A Phase 2 interventional study of HTX-011 and Saline Placebo in Postoperative Pain, sponsored by Heron Therapeutics. Completed at 24 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-02.
Sponsored by Heron Therapeutics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 364 studies testing bupivacaine in Pain, Postoperative — 57 open to participants now, 60 under way, 5 of them phase 3. Bupivacaine · Pain, Postoperative.
Among the 364 studies testing bupivacaine in Pain, Postoperative, this one is the 16th largest by enrollment, is one of 31 that started in 2017, is one of 43 in phase 2, and was the 103rd registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.
Browse Pain, Postoperative studies →57 of the 364 studies testing bupivacaine in Pain, Postoperative are open now, in 8 countries. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
Hitit University · Sites in Turkey
Ages 18–75
Wah Medical college , POF hospital · Sites in Pakistan
Ages 18–60
Tianjin First Central Hospital · Sites in China
Ages 18–80
Erkan Gol · Sites in Turkey
Ages 18+ · Women only
By country, each count listing its studies:
Bupivacaine: first FDA approval 1972 (MARCAINE HYDROCHLORIDE PRESERVATIVE FREE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
364 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 57 · Phase 3 53 · Phase 4 133
First in 2004; this study’s year is marked. 31 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 285 is above the median of 75 across 4,829 interventional studies indexed under Pain, Postoperative.
Median enrollment 70 across the 364 interventional studies. Of the 258 that completed or were terminated, 106 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 364 have an industry lead sponsor. The 10 most frequent:
Heron Therapeutics is the lead sponsor of 26 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 12 (86%) have results posted.
20 studies in Pain, Postoperative by Heron Therapeutics: none open now, 1 under way, none of them phase 3. Of 18 finished, 16 (89%) have results posted.
Among the 20 studies in Pain, Postoperative by Heron Therapeutics, this one is the 5th largest by enrollment, is one of 4 that started in 2017, is one of 10 in phase 2, and was the 5th registered.
Heron Therapeutics’s Pain, Postoperative studies by the year they started, since 2015.
22 of the studies testing bupivacaine in Pain, Postoperative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06350981Phase 3Foundation for Orthopaedic Research and EducationAnalgesic Requirement for Post-Operative Pain Control in TLIP Interbody Fusion | 2027-01-01 |
| NCT06077422Phase 3Rutgers, The State University of New JerseyExparel vs. Marcaine ESP Block for Post-cardiac Surgical Pain | 2027-01-11 |
| NCT07650760Wah Medical college , POF hospitalComparison of Intraperitoneal Bupivacaine and Saline Irrigation for Pain Relief After Laparoscopic Cholecystectomy | 2026-12 |
| NCT03737292Milton S. Hershey Medical CenterLiposomal Bupivacaine Versus Plain Bupivacaine After Intercostal Injections For Pain Management After Thoracoscopy | 2026-12 |
| NCT02381353Mayo ClinicExparel Injection for Postoperative Orbital Pain | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 364 studies testing bupivacaine in Pain, Postoperative, from their registry updates:
Among Heron Therapeutics’s 20 in Pain, Postoperative:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2b, randomized, double-blind, saline placebo- and active-controlled, multicenter study in subjects undergoing primary unilateral total knee arthroplasty (TKA) to evaluate the analgesic efficacy, safety, and pharmacokinetics (PK) of HTX-011 administered via infiltration to the surgical site.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HTX-011 (bupivacaine/meloxicam), 200 mg/6 mg via instillation
Drug: HTX-011
HTX-011 (bupivacaine/meloxicam), 200 mg/6 mg via injection and instillation (combination)
Drug: HTX-011
Saline placebo via injection
Drug: Saline Placebo
Bupivacaine HCl without epinephrine, 125 mg via injection
Drug: Bupivicaine HCl
HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg via instillation
Drug: HTX-011
HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg via instillation; Ropivacaine, 50 mg via injection
Drug: HTX-011 · Drug: Ropivacaine
Saline placebo via injection
Drug: Saline Placebo
Bupivacaine HCl without epinephrine, 125 mg via injection
Drug: Bupivicaine HCl
Drug pages: Bupivacaine · Meloxicam
HTX-011 (bupivacaine/meloxicam), via instillation
Saline placebo via injection
Bupivacaine HCl without epinephrine
Ropivacaine, via injection
Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores at Rest (NRS-R) Through 48 Hours Postsurgery (AUC0-48).
Pain intensity is assessed at rest using an 11-point NRS (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable" (using windowed worst observation carried forward to adjust for opioid rescue medication use). The theoretical range of AUC0-48 is 0-480.
Time frame: 48 hours
Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores at Rest (NRS-R) Through 72 Hours Postsurgery (AUC0-72).
Pain intensity is assessed at rest using an 11-point NRS (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable" (using windowed worst observation carried forward to adjust for opioid rescue medication use). The theoretical range of AUC0-72 is 0-720.
Time frame: 72 hours
Mean Total Postoperative Opioid Consumption (in Morphine Equivalents)
Time frame: 72 hours
| Milestone | Cohort 1, Group 1: HTX-011 | Cohort 1, Group 2: HTX-011 | Cohort 1, Group 3: Saline Placebo | Cohort 1, Group 4: Bupivacaine HCI | Cohort 2, Group 1: HTX-011 | Cohort 2, Group 2: HTX-011 + Ropivacaine | Cohort 2, Group 3: Saline Placebo | Cohort 2, Group 4: Bupivacaine HCI |
|---|---|---|---|---|---|---|---|---|
| Started | 20 | 22 | 11 | 10 | 58 | 56 | 53 | 55 |
| Completed | 20 | 22 | 11 | 10 | 58 | 54 | 51 | 55 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Pain intensity is assessed at rest using an 11-point NRS (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable" (using windowed worst observation carried forward to adjust for opioid rescue medication use). The theoretical range of AUC0-48 is 0-480.
| pain intensity score*hr | Cohort 1, Group 1: HTX-011 | Cohort 1, Group 2: HTX-011 | Cohort 1, Group 3: Saline Placebo | Cohort 1, Group 4: Bupivacaine HCI | Cohort 2, Group 1: HTX-011 | Cohort 2, Group 2: HTX-011 + Ropivacaine | Cohort 2, Group 3: Saline Placebo | Cohort 2, Group 4: Bupivacaine HCI |
|---|---|---|---|---|---|---|---|---|
| Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores at Rest (NRS-R) Through 48 Hours Postsurgery (AUC0-48). | 386.12 ± 82.930 | 391.56 ± 84.450 | 405.82 ± 97.549 | 347.56 ± 103.422 | 322.08 ± 99.669 | 307.25 ± 127.674 | 396.36 ± 77.468 | 352.74 ± 100.887 |
Pain intensity is assessed at rest using an 11-point NRS (0-10) where 0 represents "no pain" and 10 represents "worst pain imaginable" (using windowed worst observation carried forward to adjust for opioid rescue medication use). The theoretical range of AUC0-72 is 0-720.
| pain intensity score*hr | Cohort 1, Group 1: HTX-011 | Cohort 1, Group 2: HTX-011 | Cohort 1, Group 3: Saline Placebo | Cohort 1, Group 4: Bupivacaine HCI | Cohort 2, Group 1: HTX-011 | Cohort 2, Group 2: HTX-011 + Ropivacaine | Cohort 2, Group 3: Saline Placebo | Cohort 2, Group 4: Bupivacaine HCI |
|---|---|---|---|---|---|---|---|---|
| Mean Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) Pain Intensity Scores at Rest (NRS-R) Through 72 Hours Postsurgery (AUC0-72). | 543.14 ± 142.566 | 560.85 ± 136.099 | 576.44 ± 150.815 | 468.58 ± 179.687 | 471.19 ± 149.443 | 452.54 ± 194.095 | 577.93 ± 125.102 | 516.93 ± 152.512 |
| morphine milligram equivalent (MME) | Cohort 1, Group 1: HTX-011 | Cohort 1, Group 2: HTX-011 | Cohort 1, Group 3: Saline Placebo | Cohort 1, Group 4: Bupivacaine HCI | Cohort 2, Group 1: HTX-011 | Cohort 2, Group 2: HTX-011 + Ropivacaine | Cohort 2, Group 3: Saline Placebo | Cohort 2, Group 4: Bupivacaine HCI |
|---|---|---|---|---|---|---|---|---|
| Mean Total Postoperative Opioid Consumption (in Morphine Equivalents) | 65.53 ± 31.615 | 66.86 ± 31.154 | 70.41 ± 18.057 | 60.70 ± 29.903 | 64.39 ± 27.889 | 60.32 ± 34.949 | 73.55 ± 34.448 | 68.35 ± 29.169 |
Collected over 28 Days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1, Group 1: HTX-011 | 0/20 (0%) | 0/20 (0%) | 19/20 (95%) |
| Cohort 1, Group 2: HTX-011 | 0/22 (0%) | 2/22 (9.1%) | 22/22 (100%) |
| Cohort 1, Group 3: Saline Placebo | 0/11 (0%) | 0/11 (0%) | 11/11 (100%) |
| Cohort 1, Group 4: Bupivacaine HCI | 0/10 (0%) | 1/10 (10%) | 10/10 (100%) |
| Cohort 2, Group 1: HTX-011 | 0/58 (0%) | 1/58 (1.7%) | 55/58 (94.8%) |
| Cohort 2, Group 2: HTX-011 + Ropivacaine | 0/56 (0%) | 4/56 (7.1%) | 50/56 (89.3%) |
| Cohort 2, Group 3: Saline Placebo | 0/53 (0%) | 3/53 (5.7%) | 50/53 (94.3%) |
| Cohort 2, Group 4: Bupivacaine HCI | 0/55 (0%) | 2/55 (3.6%) | 49/55 (89.1%) |
| Event | Cohort 1, Group 1: HTX-011 | Cohort 1, Group 2: HTX-011 | Cohort 1, Group 3: Saline Placebo | Cohort 1, Group 4: Bupivacaine HCI | Cohort 2, Group 1: HTX-011 | Cohort 2, Group 2: HTX-011 + Ropivacaine | Cohort 2, Group 3: Saline Placebo | Cohort 2, Group 4: Bupivacaine HCI |
|---|---|---|---|---|---|---|---|---|
| SyncopeNervous system disorders | 0/20 | 0/22 | 0/11 | 1/10 | 0/58 | 0/56 | 0/53 | 0/55 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/20 | 1/22 | 0/11 | 0/10 | 1/58 | 1/56 | 0/53 | 1/55 |
| Post procedural haematomaInjury, poisoning and procedural complications | 0/20 | 1/22 | 0/11 | 0/10 | 0/58 | 0/56 | 0/53 | 0/55 |
| HyponatraemiaMetabolism and nutrition disorders | 0/20 | 0/22 | 0/11 | 0/10 | 0/58 | 0/56 | 1/53 | 0/55 |
| Cholecystitis acuteHepatobiliary disorders | 0/20 | 0/22 | 0/11 | 0/10 | 0/58 | 0/56 | 1/53 | 0/55 |
| HaematomaVascular disorders | 0/20 | 0/22 | 0/11 | 0/10 | 0/58 | 0/56 | 1/53 | 0/55 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/20 | 0/22 | 0/11 | 0/10 | 0/58 | 0/56 | 0/53 | 1/55 |
| Urinary retentionRenal and urinary disorders | 0/20 | 0/22 | 0/11 | 0/10 | 0/58 | 1/56 | 0/53 | 0/55 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/20 | 0/22 | 0/11 | 0/10 | 0/58 | 1/56 | 0/53 | 0/55 |
| Post procedural cellulitisInfections and infestations | 0/20 | 0/22 | 0/11 | 0/10 | 0/58 | 1/56 | 0/53 | 0/55 |
| Event | Cohort 1, Group 1: HTX-011 | Cohort 1, Group 2: HTX-011 | Cohort 1, Group 3: Saline Placebo | Cohort 1, Group 4: Bupivacaine HCI | Cohort 2, Group 1: HTX-011 | Cohort 2, Group 2: HTX-011 + Ropivacaine | Cohort 2, Group 3: Saline Placebo | Cohort 2, Group 4: Bupivacaine HCI |
|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 14/20 | 16/22 | 6/11 | 4/10 | 29/58 | 30/56 | 25/53 | 30/55 |
| ConstipationGastrointestinal disorders | 8/20 | 10/22 | 2/11 | 3/10 | 14/58 | 21/56 | 12/53 | 18/55 |
| HypertensionVascular disorders | 2/20 | 3/22 | 1/11 | 4/10 | 11/58 | 8/56 | 8/53 | 7/55 |
| DizzinessNervous system disorders | 5/20 | 5/22 | 4/11 | 3/10 | 9/58 | 8/56 | 9/53 | 8/55 |
| VomitingGastrointestinal disorders | 7/20 | 6/22 | 4/11 | 2/10 | 15/58 | 14/56 | 10/53 | 15/55 |
| HypokalaemiaMetabolism and nutrition disorders | 2/20 | 1/22 | 3/11 | 1/10 | 3/58 | 6/56 | 4/53 | 6/55 |
| LeukocytosisBlood and lymphatic system disorders | 1/20 | 5/22 | 2/11 | 1/10 | 4/58 | 6/56 | 0/53 | 1/55 |
| PyrexiaGeneral disorders | 1/20 | 5/22 | 0/11 | 2/10 | 8/58 | 8/56 | 2/53 | 8/55 |
| TachycardiaCardiac disorders | 4/20 | 4/22 | 1/11 | 0/10 | 9/58 | 9/56 | 11/53 | 6/55 |
| HyperglycaemiaMetabolism and nutrition disorders | 0/20 | 0/22 | 0/11 | 2/10 | 1/58 | 2/56 | 0/53 | 0/55 |
| Age, Categorical(Participants) | Cohort 1, Group 1: HTX-011 | Cohort 1, Group 2: HTX-011 | Cohort 1, Group 3: Saline Placebo | Cohort 1, Group 4: Bupivacaine HCI | Cohort 2, Group 1: HTX-011 | Cohort 2, Group 2: HTX-011 + Ropivacaine | Cohort 2, Group 3: Saline Placebo | Cohort 2, Group 4: Bupivacaine HCI | Total |
|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 12 | 17 | 5 | 4 | 31 | 34 | 36 | 38 | 177 |
| >=65 years | 8 | 5 | 6 | 6 | 27 | 22 | 17 | 17 | 108 |
| Age, Continuous(years) | Cohort 1, Group 1: HTX-011 | Cohort 1, Group 2: HTX-011 | Cohort 1, Group 3: Saline Placebo | Cohort 1, Group 4: Bupivacaine HCI | Cohort 2, Group 1: HTX-011 | Cohort 2, Group 2: HTX-011 + Ropivacaine | Cohort 2, Group 3: Saline Placebo | Cohort 2, Group 4: Bupivacaine HCI | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 62.1 ± 7.52 | 58.6 ± 7.44 | 64.9 ± 4.64 | 65.3 ± 11.62 | 62.5 ± 8.63 | 63.2 ± 9.36 | 61.5 ± 8.31 | 61.4 ± 9.37 | 62.1 ± 8.71 |
| Sex: Female, Male(Participants) | Cohort 1, Group 1: HTX-011 | Cohort 1, Group 2: HTX-011 | Cohort 1, Group 3: Saline Placebo | Cohort 1, Group 4: Bupivacaine HCI | Cohort 2, Group 1: HTX-011 | Cohort 2, Group 2: HTX-011 + Ropivacaine | Cohort 2, Group 3: Saline Placebo | Cohort 2, Group 4: Bupivacaine HCI | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 13 | 9 | 7 | 5 | 26 | 27 | 25 | 35 | 147 |
| Male | 7 | 13 | 4 | 5 | 32 | 29 | 28 | 20 | 138 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1, Group 1: HTX-011 | Cohort 1, Group 2: HTX-011 | Cohort 1, Group 3: Saline Placebo | Cohort 1, Group 4: Bupivacaine HCI | Cohort 2, Group 1: HTX-011 | Cohort 2, Group 2: HTX-011 + Ropivacaine | Cohort 2, Group 3: Saline Placebo | Cohort 2, Group 4: Bupivacaine HCI | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 7 | 10 | 3 | 1 | 9 | 16 | 12 | 16 | 74 |
| Not Hispanic or Latino | 13 | 12 | 8 | 9 | 49 | 40 | 41 | 39 | 211 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1, Group 1: HTX-011 | Cohort 1, Group 2: HTX-011 | Cohort 1, Group 3: Saline Placebo | Cohort 1, Group 4: Bupivacaine HCI | Cohort 2, Group 1: HTX-011 | Cohort 2, Group 2: HTX-011 + Ropivacaine | Cohort 2, Group 3: Saline Placebo | Cohort 2, Group 4: Bupivacaine HCI | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 3 |
| Asian | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 5 | 3 | 2 | 3 | 6 | 5 | 8 | 7 | 39 |
| White | 15 | 18 | 9 | 7 | 51 | 49 | 45 | 47 | 241 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Cohort 1, Group 1: HTX-011 | Cohort 1, Group 2: HTX-011 | Cohort 1, Group 3: Saline Placebo | Cohort 1, Group 4: Bupivacaine HCI | Cohort 2, Group 1: HTX-011 | Cohort 2, Group 2: HTX-011 + Ropivacaine | Cohort 2, Group 3: Saline Placebo | Cohort 2, Group 4: Bupivacaine HCI | Total |
|---|---|---|---|---|---|---|---|---|---|
| United States | 20 | 22 | 11 | 10 | 58 | 56 | 53 | 55 | 285 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2017 to primary completion in Apr 2018, 15 months.
Results were first posted in Oct 2021, 3 years 6 months after primary completion. A results delay was requested in Jun 2018.
Of 49 industry-sponsored phase 2 interventional studies under Pain, Postoperative, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 11. This study's 15 months is above that.
Counting every sponsor, half of 139 studies reached it within 12 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bupivacaine · Meloxicam